Type to search

Tridek-One SAS

Share

Tridek-One SAS

Tridek-One is a private biotechnology company formed out of INSERM (Paris, France), and backed by a strong group of international investors that includes Pureos Bioventures, AdBio partners, Bpifrance, Advent Life Sciences and Bioqube Ventures. The company develops first-in-class immune checkpoint agonists to restore the immune balance in patients living with auto-immune diseases.
Created in 2018 by Dr. Giuseppina Caligiuri and Professor Antonino Nicoletti and based in Paris, France, Tridek-One raised €3M ($3.02M) in 2019 in a first funding round supported by two venture funds, AdBio partners and Advent Life Sciences.